Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
Abstract Background Bronchial asthma is an inflammatory disease of the airways. Beclomethasone dipropionate/Formoterol (BDP/F) and Fluticasone furoate/Vilanterol (FF/V) are two of the most effective LABA/ICS combinations for managing persistent bronchial asthma. Aim of the study was to compare the o...
Main Authors: | Roberto W. Dal Negro, Luca Bonadiman, Paola Turco |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2018-06-01
|
Series: | Multidisciplinary Respiratory Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40248-018-0131-x |
Similar Items
-
Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
by: Furuhashi K, et al.
Published: (2019-09-01) -
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01) -
Extrafine combination beclomethasone dipropionate/ formoterol therapy in obstructive lung diseases
by: I. N. Trofimenko, et al.
Published: (2020-08-01) -
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01) -
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
by: Bhatt SP, et al.
Published: (2017-01-01)